Why Partner with Us?
Research and development is the heart and soul of Bristol-Myers Squibb’s BioPharma strategy, whether we are working alone or in a partnership. With over 50 compounds in development, a network of research facilities around the globe, and an annual R&D budget of almost $4.0 billion, Bristol-Myers Squibb is considered one of the premier R&D organizations in the industry, ranking #1 in R&D efficiency in the 2012 KMR R&D General Metrics Study*.
Combining great science with rigorous development focused on unmet medical needs, we bring innovative medicines to patients. To accomplish this goal, we have engaged in numerous collaborations and continue to engage with top tier organizations and research institutes around the world. Collaborations are an integral part of Bristol-Myers Squibb’s strategy to strengthen and sustain our pipeline in our strategic and exploratory therapeutic areas, as well as our mission to discover develop and deliver innovative medicines to help patients prevail over serious diseases.
We have successfully built multiple blockbuster franchises and consistently realized more than half our total pharmaceutical sales from partnered or in-licensed products. Partnering is in the DNA of Bristol-Myers Squibb and we have established a collaborative culture to do what is best each of these partnerships, the products and the patients we serve. Following a collaborative evaluation and negotiation process, an experienced alliance professional actively manages the collaboration. The engagement of our senior leadership combined with Bristol-Myers Squibbs’ collaborative culture creates an unparalleled commitment to maximizing the value of the asset, through extensive life cycle management, a process we call “Pipeline in a Product”. We invite you to contact us with information about your breakthrough technology or medicine and your potential interest in partnering with Bristol-Myers Squibb.
Come join and explore other parts of our site for more information on our partnering success, our current areas of interest for new medicines and technologies and our alliance management philosophy.